

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI926720

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT		03/28/2025
RECEIVING PARTY DATA		
Company Name:	EAGLE PHARMACEUTICALS, INC.	
Street Address:	50 Tice Blvd, Suite 315	
City:	Woodcliff Lake	
State/Country:	NEW JERSEY	
Postal Code:	07677	
PROPERTY NUMBERS Total: 74		
Property Type	Number	
Application Number:	11904067	
Application Number:	11973485	
Application Number:	12545036	
Application Number:	12563821	
Application Number:	12884653	
Application Number:	13016473	
Application Number:	13618532	
Application Number:	13767672	
Application Number:	13806624	
Application Number:	13838090	
Application Number:	13838267	
Application Number:	14031879	
Application Number:	14711359	
Application Number:	14714578	
Application Number:	14820291	
Application Number:	14857064	
Application Number:	14982813	
Application Number:	15008819	
Application Number:	15008827	
Application Number:	15013424	

PATENT

Property Type	Number
Application Number:	15013436
Application Number:	15048416
Application Number:	15184464
Application Number:	15184488
Application Number:	29403209
Application Number:	15432335
Application Number:	15432378
Patent Number:	10363259
Application Number:	16099265
Application Number:	16297125
Patent Number:	9801892
Patent Number:	9180088
Application Number:	13858771
Application Number:	16509920
Application Number:	16508741
Application Number:	15588002
Application Number:	17052572
Application Number:	17679883
Application Number:	17740990
Application Number:	17412623
Application Number:	17529791
Application Number:	16762229
Application Number:	17379534
Application Number:	17540878
Application Number:	17835236
Application Number:	17995602
Application Number:	17995604
Application Number:	17995606
Application Number:	17995608
Application Number:	63313030
Application Number:	63343750
Application Number:	17022574
Application Number:	17819726
Application Number:	63296376
Application Number:	17898558
Application Number:	17898637
Application Number:	17898984
Patent Number:	11872214

Property Type	Number
Application Number:	18498259
Application Number:	18646171
Application Number:	18646329
Patent Number:	11844783
Application Number:	18296290
Application Number:	18296268
Application Number:	18109421
Application Number:	18506633
Application Number:	18737637
Application Number:	18470621
Application Number:	18470952
Application Number:	18456772
Application Number:	62420555
Application Number:	62332842
PCT Number:	US1530581
PCT Number:	US1618703

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2023704750

Email: ipteam@cogencyglobal.com

Correspondent Name: Joanna McCall

Address Line 1: 1025 Connecticut Ave NW, Suite 712

Address Line 2: Cogency Global Inc.

Address Line 4: Washington, DISTRICT OF COLUMBIA 20036

ATTORNEY DOCKET NUMBER:	2703122 JM
NAME OF SUBMITTER:	Joanna McCall
SIGNATURE:	/Joanna McCall/
DATE SIGNED:	04/01/2025

Total Attachments: 9

source=Eagle Pharma - Patent Release#page1.tiff
source=Eagle Pharma - Patent Release#page2.tiff
source=Eagle Pharma - Patent Release#page3.tiff
source=Eagle Pharma - Patent Release#page4.tiff
source=Eagle Pharma - Patent Release#page5.tiff
source=Eagle Pharma - Patent Release#page6.tiff
source=Eagle Pharma - Patent Release#page7.tiff
source=Eagle Pharma - Patent Release#page8.tiff
source=Eagle Pharma - Patent Release#page9.tiff

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “Release”), dated as of March 28, 2025, is made by JPMORGAN CHASE BANK, N.A., chartered under the laws of Ohio and having an address of 10 South Dearborn, Chicago, Illinois 60603, in its capacity as administrative agent (the “Administrative Agent”), in favor of EAGLE PHARMACEUTICALS, INC., a Delaware corporation and having an address of 50 Tice Blvd, Suite 315 (“Eagle”).

WHEREAS, reference is made to the following Confirmatory Grants of Security Interest in United States Patents by and among Eagle and the Administrative Agent pursuant to which Eagle granted a security interest to the Administrative Agent in certain patents listed on Schedule I: (i) dated January 26, 2017, recorded at the USPTO on January 26, 2017 at Reel 041095 Frame 0554; (ii) dated August 8, 2017, recorded at the USPTO on August 21, 2017 at Reel 043346 Frame 0871; (iii) dated November 8, 2019, recorded at the USPTO on October 24, 2022 at Reel 061513 Frame 0804; (iv) dated November 1, 2022, recorded at the USPTO on November 1, 2022 at Reel 061615 Frame 0013; and (v) dated October 11, 2024, recorded at the USPTO on October 11, 2024 at Reel 068873 Frame 0898 (the “Notices”; all capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Notices); and

WHEREAS, the Administrative Agent, on behalf of itself and each of the other Secured Parties, now agrees to terminate and grant a release of the security interest in and lien upon the patents listed on Schedule I attached hereto owned by Eagle as provided in this Release;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent, on behalf of itself and the other Secured Parties, hereby agrees as follows:

1. Release of Security Interest. The Administrative Agent, without representation or warranty of any kind, hereby releases, discharges, terminates and cancels all of its security interest in and to and general lien upon, and any conditional collateral assignments of, the patents owned by Eagle listed on Schedule I annexed hereto and made a part hereof, together with all registrations and recordings thereof, all applications in connection therewith, all products and proceeds thereof and any goodwill of the business connected with, and symbolized by, any of the foregoing, and assigns, conveys and transfers to Eagle, without recourse, all of the Administrative Agent’s right, title and interest in such patents and patent applications, and any right, title or interest of the Administrative Agent in such patents and patent applications shall hereby cease and be void.

2. No Other Release. The foregoing release is a release only of the security interest in the patents listed on Schedule I attached hereto and does not constitute a release of the security interest in any other patents.

3. USPTO. The Administrative Agent authorizes the United States Patent and Trademark Office (the “USPTO”) and any other applicable governmental authority to record this Release and understands and agrees that this Release may be recorded by or for Eagle with the USPTO or any similar office or agency within or outside the United States.

**JPMORGAN CHASE BANK, N.A., as Administrative
Agent**

A handwritten signature in dark ink, appearing to read "D. Luby", is written over a horizontal line.

By: _____

Name: Daniel Luby

Title: Executive Director

Schedule I

UNITED STATES REGISTERED PATENTS

Patent/Application Number	Product	Title	Country	Status
2669727	Argatroban	ALCOHOL FREE FORMULATION OF ARGATROBAN	Canada	Issued
5624766	Argatroban	ALCOHOL FREE FORMULATION OF ARGATROBAN	Japan	Issued
7,589,106	Argatroban	ALCOHOL FREE FORMULATION OF ARGATROBAN	US	Issued
7,687,516	Argatroban	ALCOHOL FREE FORMULATION OF ARGATROBAN	US	Issued
13618,532	Argatroban	ALCOHOL FREE FORMULATION OF ARGATROBAN	US	Pending
13749829.1	Bendamustine	FORMULATIONS OF BENDAMUSTINE	EP	Pending
2787568	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Canada	Pending
2,864,118	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Canada	Pending
2,867,295	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Canada	Pending
2528602	Bendamustine	Formulations of Bendamustine	EP	Pending
5795600	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Japan	Issued
2015-160351	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Japan	Pending
2014-556835	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Japan	Pending
2015-501813	Bendamustine	FORMULATIONS OF BENDAMUSTINE	Japan	Pending
8,609,707	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Issued
9,265,831	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Issued
15,013,424	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
15,013,436	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
13/767,672	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
9,034,908	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Issued
9,144,568	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Issued
14/857,064	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
15/008,819	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
15/008,827	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
15/184,464	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
15/184,488	Bendamustine	FORMULATIONS OF BENDAMUSTINE	US	Pending
2,867,343	Bendamustine	METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR	Canada	Pending

141298412 v1

PATENT
REEL: 041095 FRAME: 0560

		ADMINISTRATION		
13765020.6	Bendamustine	METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION	EP	Pending
2015-591814	Bendamustine	METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION	Japan	Pending
9,000,021	Bendamustine	METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION	US	Issued
14/820,291	Bendamustine	METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION	US	Pending
PCT/US2015/030581	Bivalirudin	AQUEOUS BUFFER-FREE BIVALIRUDIN COMPOSITIONS	PCT	Pending
14/711,359	Bivalirudin	AQUEOUS BUFFER-FREE BIVALIRUDIN COMPOSITIONS	US	Pending
14/982,813	Bivalirudin	AQUEOUS BUFFER-FREE BIVALIRUDIN COMPOSITIONS	US	Pending
7803762	Bivalirudin	READY-TO-USE BIVALIRUDIN COMPOSITIONS	US	Issued
7713928	Bivalirudin	READY-TO-USE BIVALIRUDIN COMPOSITIONS	US	Issued
8,431,539	Daptomycin	FORMULATIONS OF DAPTOMYCIN	US	Issued
62/420,555	Fulvestrant	Fulvestrant Compositions and Methods of Their Use	US	Pending
62/332,842	Fulvestrant	Fulvestrant Formulations	US	Pending
PCT/US2016/018703	Pemetrexed	PEMETREXED FORMULATIONS	PCT	Pending
15/048,416	Pemetrexed	Pemetrexed Formulations	US	Pending

141298412 v1

PATENT
REEL: 041095 FRAME: 0561

13/806,624	Pemetrexed	PHARMACEUTICAL COMPOSITIONS CONTAINING PEMETREXED HAVING EXTENDED STORAGE STABILITY	US	Pending
EU002014902-0001	Vial	VIAL WITH COLLAR LABEL	EP	Issued
EU002014902-0002	Vial	VIAL WITH COLLAR LABEL	EP	Issued
D676,572	Vial	VIAL WITH COLLAR LABEL	US	Issued

PATENT
REEL: 041095 FRAME: 0562

141298412 v1

RECORDED: 01/26/2017

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
15432335	14-FEB-2017	FORMULATIONS OF BENDAMUSTINE	Likely EAGLE PHARMACEUTICALS, INC.	PENDING
15432378	14-FEB-2017	FORMULATIONS OF BENDAMUSTINE	Likely EAGLE PHARMACEUTICALS, INC.	PENDING

PATENT
REEL: 070703 FRAME: 0531

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
10363259 20180289722 15789267	30-JUL-2019 10-JUL-2019 20-OCT-2017	FULVESTRANT FOMULATIONS	EAGLE PHARMACEUTICALS, INC.	ISSUED
20190134059 16099265	09-MAY-2019 06-NOV-2018	FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20190201405 16297125	04-JUL-2019 08-MAR-2019	PEMETREXED FORMULATIONS	EAGLE PHARMACEUTICALS, INC. (Applicant)	PUBLISHED
9801892 20160058773 14934428	31-OCT-2017 03-MAR-2016 06-NOV-2015	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC. (Applicant)	ISSUED
9180088 20090227549 12380968	10-NOV-2015 10-SEP-2009 05-MAR-2009	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC. (Applicant)	ISSUED
20130267489 13858771	10-OCT-2013 08-APR-2013	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC	PUBLISHED
16509920	12-JUL-2019	FORMULATIONS OF BENDAMUSTINE	EAGLE PHARMACEUTICALS, INC.	PENDING
16508741	11-JUL-2019	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC	PENDING
15588002	30-SEP-2019	FORMULATIONS OF BENDAMUSTINE	EAGLE PHARMACEUTICALS, INC.	PENDING

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
20210236467 17052572	05-AUG-2021 03-NOV-2020	DANTROLENE FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20220323584 17679883	13-OCT-2022 24-FEB-2022	FORMULATIONS OF BENDAMUSTINE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20220265829 17740990	25-AUG-2022 10-MAY-2022	FORMULATIONS OF BENDAMUSTINE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20210393594 17412623	23-DEC-2021 26-AUG-2021	FORMULATIONS OF BENDAMUSTINE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20220072132 17529791	10-MAR-2022 18-NOV-2021	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20200360284 16762229	19-NOV-2020 07-MAY-2020	FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20210346396 17379534	11-NOV-2021 19-JUL-2021	FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20220087980 17540878	24-MAR-2022 02-DEC-2021	METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20220296603 17835236	22-SEP-2022 08-JUN-2022	PEMETREXED FORMULATIONS	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
17995602	06-OCT-2022	METHODS OF TREATING SARS- COV-2 INFECTIONS	EAGLE PHARMACEUTICALS, INC.	PENDING

PATENT

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
17995604	06-OCT-2022	METHODS OF TREATING SEVERE ACUTE RESPIRATORY SYNDROME	EAGLE PHARMACEUTICALS, INC.	PENDING
17995606	06-OCT-2022	METHODS OF TREATING CORONAVIRUS INFECTIONS	EAGLE PHARMACEUTICALS, INC.	PENDING
17995608	06-OCT-2022	METHODS OF TREATING VIRAL INFECTIONS	EAGLE PHARMACEUTICALS, INC.	PENDING
20200360284 16762229	19-NOV-2020 07-MAY-2020	FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
63313030	23-FEB-2022	FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PENDING
63343750	19-MAY-2022	FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE	EAGLE PHARMACEUTICALS, INC.	PENDING
20220072132 17529791	10-MAR-2022 18-NOV-2021	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
20210260076 17022574	26-AUG-2021 16-SEP-2020	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC.	PUBLISHED
17819726	15-AUG-2022	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC.	PENDING
63296376	04-JAN-2022	FULVESTRANT FORMULATIONS	EAGLE PHARMACEUTICALS, INC.	PENDING

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
		AND METHODS OF THEIR USE		
17898558	30-AUG-2022	PEMETREXED FORMULATIONS TRACK 1	EAGLE PHARMACEUTICALS, INC.	PENDING
17898637	30-AUG-2022	PEMETREXED FORMULATIONS TRACK 1	EAGLE PHARMACEUTICALS, INC.	PENDING
17898984	30-AUG-2022	PEMETREXED FORMULATIONS TRACK 1	EAGLE PHARMACEUTICALS, INC.	PENDING

Title	Country Name	Status	Date Filed	Application #	Grant Date	Patent #	Recorded Owner
Formulations Of Bendamustine	United States of America	Issued	12/14/2022	18/081,251	01/16/2024	11872214	Eagle Pharmaceuticals, Inc.
Formulations Of Bendamustine	United States of America	Published	10/31/2023	18/498,259			Eagle Pharmaceuticals, Inc.
Formulations Of Bendamustine	United States of America	Pending	04/25/2024	18/646,171			Eagle Pharmaceuticals, Inc.
Formulations Of Bendamustine	United States of America	Pending	04/25/2024	18/646,329			Eagle Pharmaceuticals, Inc.
Formulations Of Bendamustine	United States of America	Issued	12/14/2022	18/081,238	12/19/2023	11844783	Eagle Pharmaceuticals, Inc.
Formulations Of Bendamustine	United States of America	Published	04/05/2023	18/296,290			Eagle Pharmaceuticals, Inc.
Formulations Of Bendamustine	United States of America	Published	04/05/2023	18/296,268			Eagle Pharmaceuticals, Inc.
Fulvestrant Formulations And Methods Of Their Use	United States of America	Published	02/14/2023	18/109,421			Eagle Pharmaceuticals, Inc.
Fulvestrant Formulations	United States of America	Published	11/10/2023	18/506,633			Eagle Pharmaceuticals, Inc.

Title	Country Name	Status	Date Filed	Application #	Grant Date	Patent #	Recorded Owner
Fulvestrant Formulations And Methods Of Their Use	United States of America	Pending	06/07/2024	18/737,637			Eagle Pharmaceuticals, Inc.
PEMETREXED FORMULATIONS	United States of America	Published	09/20/2023	18470621			Eagle Pharmaceuticals, Inc.
PEMETREXED FORMULATIONS	United States of America	Allowed	09/20/2023	18470952			Eagle Pharmaceuticals, Inc.
PEMETREXED FORMULATIONS	United States of America	Pending	08/28/2023	18456772			Eagle Pharmaceuticals, Inc.

PATENT

RECORDED: 04/01/2025

REEL: 070703 FRAME: 0535